Candel Therapeutics, Inc.
NASDAQ•CADL
CEO: Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-07-27
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Contact Information
Market Cap
$256.39M
P/E (TTM)
-29.5
17.9
Dividend Yield
--
52W High
$9.08
52W Low
$4.25
52W Range
Rank58Top 85.6%
2.3
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 2.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025
Financial Dashboard
Q4 2025 Data
Revenue
$0.00+0.00%
4-Quarter Trend
EPS
-$0.54+0.00%
4-Quarter Trend
FCF
-$10.98M+0.00%
4-Quarter Trend
Earnings Highlights
Key Highlights
No Data Available
Risk Factors
No Data Available
Outlook
No Data Available
Peer Comparison
Revenue (TTM)
$40.52M
$17.17M
$12.74M
Gross Margin (Latest Quarter)
100.0%
100.0%
96.7%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| CAPR | $1.39B | -17.0 | -71.0% | 11.5% |
| DRTS | $611.34M | -14.4 | -57.3% | 12.9% |
| CTNM | $474.88M | -6.7 | -30.1% | 3.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Deep Research
Next earnings:May 7, 2026
EPS:-$0.36
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data